AMF Tjanstepension AB Raises Stake in Cencora, Inc. (NYSE:COR)

AMF Tjanstepension AB increased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 147.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,207 shares of the company's stock after acquiring an additional 47,193 shares during the period. AMF Tjanstepension AB's holdings in Cencora were worth $17,799,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC boosted its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares during the period. SBI Securities Co. Ltd. purchased a new position in Cencora during the fourth quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares during the last quarter. Kentucky Trust Co purchased a new stake in shares of Cencora in the fourth quarter valued at $33,000. Finally, WASHINGTON TRUST Co raised its stake in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares of the company's stock, valued at $13,022,850. The trade was a 8.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,648 shares of company stock worth $2,862,342. 10.80% of the stock is owned by corporate insiders.

Remove Ads

Cencora Stock Up 0.3 %

Shares of COR stock traded up $0.77 on Friday, hitting $254.54. The stock had a trading volume of 2,250,571 shares, compared to its average volume of 1,521,899. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The business has a 50 day moving average price of $244.34 and a 200 day moving average price of $238.40. The company has a market cap of $49.36 billion, a PE ratio of 36.21, a P/E/G ratio of 1.31 and a beta of 0.51. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.86%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Ratings Changes

Several brokerages recently commented on COR. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. StockNews.com downgraded Cencora from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective for the company. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company boosted their target price on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.